SEYEDSINA MIRJALILI

Mr. SEYEDSINA MIRJALILI

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
ZKZahra Kiani
Zahra Kiani
SMSEYEDSINA MIRJALILI
SEYEDSINA MIRJALILI
KHKamran Heydaryan
Kamran Heydaryan
PMPouria Mohammadparast
Pouria Mohammadparast
HAHamed Aramjoo
Hamed Aramjoo
SMSobhan Mortazavi-Derazkola
Sobhan Mortazavi-Derazkola

8 March 2022 in Plasmonics
Verified
Journal Article
Closed access
PDF file
SMSEYEDSINA MIRJALILI
SEYEDSINA MIRJALILI
TMTahereh Tohidi Moghadam
Tahereh Tohidi Moghadam
RSReza H. Sajedi
Reza H. Sajedi

11 August 2025 in ACS Nano
Verified
Journal Article
Closed access
YCYeji Choi
Yeji Choi
SMSEYEDSINA MIRJALILI
SEYEDSINA MIRJALILI
AIAshif Ikbal
Ashif Ikbal
SMSean McClure
Sean McClure
MMMaziyar Kalateh Mohammadi
Maziyar Kalateh Mohammadi
CWChao Wang
Chao Wang

20 March 2025 in Micromachines
Verified
Journal Article
Open access
PDF file
MKMaziyar Kalatehmohammadi
Maziyar Kalatehmohammadi
SMSEYEDSINA MIRJALILI
SEYEDSINA MIRJALILI
AIAshif Ikbal
Ashif Ikbal
HXHao Xie
Hao Xie
CWChao Wang
Chao Wang
Thrombospondin-2 (THBS2) is a prevailing prognostic biomarker implicated in different cancer types, such as deadly colorectal, pancreas, and triple-negative breast cancers. While the current methods for cancer-relevant protein detection, such as enzyme-linked immunosorbent assay (ELISA), mass spectrometry, and immunohistochemistry, are feasible at advanced stages, they have shortcomings in sensitivity, specificity, and accessibility, particularly at low concentrations in complex biological fluids for early detection. Here, we propose and demonstrate a modular, in-solution assay design concept, Nanoparticle-Supported Rapid Electronic Detection (NasRED), as a versatile cancer screening and diagnostic platform. NasRED utilizes antibody-functionalized gold nanoparticles (AuNPs) to capture target proteins from a minute amount of sample (<10 µL) and achieve optimal performance with a short assay time by introducing active fluidic forces that act to promote biochemical reaction and accelerate signal transduction. This rapid (15 min) process serves to form AuNP clusters upon THBS2 binding and subsequently precipitate such clusters, resulting in color modulation of the test tubes that is dependent on the THBS2 concentration. Finally, a semiconductor-based, portable electronic device is used to digitize the optical signals for the sensitive detection of THBS2. High sensitivity (femtomolar level) and a large dynamic range (five orders of magnitude) are obtained to analyze THBS2 spiked in PBS, serum, whole blood, saliva, cerebrospinal fluids, and synovial fluids. High specificity is also preserved in differentiating THBS2 from other markers such as cancer antigen (CA) 19-9 and bovine serum albumin (BSA). This study highlights NasRED’s potential to enhance cancer prognosis and screening by offering a cost-effective, accessible, and minimally invasive solution.

7 May 2025 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
SMSEYEDSINA MIRJALILI
SEYEDSINA MIRJALILI
AIAshif Ikbal
Ashif Ikbal
CHChing-Wen Hou
Ching-Wen Hou
MMMaziyar Kalateh Mohammadi
Maziyar Kalateh Mohammadi
YCYeji Choi
Yeji Choi
CWChao Wang
Chao Wang

6 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YCYeji Choi
Yeji Choi
SMSEYEDSINA MIRJALILI
SEYEDSINA MIRJALILI
AIAshif Ikbal
Ashif Ikbal
SMSean McClure
Sean McClure
MMMaziyar Kalateh Mohammadi
Maziyar Kalateh Mohammadi
CWChao Wang
Chao Wang
Major challenges remain to precisely detect low-abundance proteins from diverse biofluids in a rapid and cost-effective manner. Here we present a gold nanoparticle (AuNP)-supported, rapid electronic detection (NasRED) platform with sub-femtomolar sensitivity and high specificity. Surface-functionalized AuNPs act as multivalent detectors to recognize target antigens and antibodies through high-affinity binding, subsequently forming aggregates precipitated in a microcentrifuge tube and producing a solution color change. The optical extinction of residual floating AuNPs is digitized using a customized circuitry incorporating inexpensive optoelectronic elements and feedback mechanisms for stabilized readout. Uniquely, NasRED introduces active fluidic forces through engineered centrifugation and vortex agitation, effectively promoting protein detection at low concentrations and accelerating signal generation. Using SARS-CoV-2 as a demonstration, NasRED enables detection of both antibodies and antigens from a small sample volume (6 µL), distinguishes the viral antigens from those of human coronaviruses, and delivers test results in a short time (as fast as 3,000 times more sensitive than Enzyme-Linked Immunosorbent Assay (ELISA), ∼76 aM (11 fg/mL) in human pooled serum and in the femtomolar range in diluted whole blood. For nucleocapsid protein detection, NasRED LoDs are ∼190 aM (10 fg/mL) in human saliva and ∼2 fM (100 fg/mL) in nasal fluid. Unlike laboratory-based ELISA platforms, NasRED is a one-pot, in-solution assay that eliminates the needs for washing, labeling, expensive instrumentation or highly trained operators. With low reagent costs and a compact system footprint, this modular digital platform is well-suited for accurate, near-patient diagnosis and screening of a wide range of infectious and chronic diseases.